{{Drugbox
| IUPAC_name               = (1''R'',3''R'',6''R'')-6-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-1,3-cyclohexanediol
| image                    = Axomadol_structure.png
| CAS_number               = 187219-95-0
| CAS_supplemental         = <br />187219-99-4
| ATC_prefix               = None
| ATC_suffix               = 
| PubChem                  = 10221318
| ChemSpiderID             = 8396810
| C=16 | H=25 | N=1 | O=3
| molecular_weight         = 279.375 g/mol
| smiles                   = O[C@]2(c1cc(OC)ccc1)C[C@H](O)CC[C@@H]2CN(C)C
| StdInChI                 = 1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m1/s1
| StdInChIKey              = LQJLLAOISDVBJM-FMKPAKJESA-N
| bioavailability          = 
| protein_bound            = 
| metabolism               = 
| elimination_half-life    = 
| excretion                = 
| pregnancy_category       = 
| legal_US = IND
| legal_US_comment =
| routes_of_administration = 
}}

'''Axomadol''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (code name '''EN3324''') is a [[Chemical synthesis|synthetic]], [[central nervous system|centrally-acting]] [[opioid]] [[analgesic]] of the benzenoid class which was under investigation by [[Endo Pharmaceuticals]] in collaboration with [[Gr端nenthal GmbH|Gr端nenthal]] for the treatment of chronic, moderate to severe [[low back pain|lower back pain]] and [[arthrosis]].<ref name="Endo2011-1">{{cite press release | title = Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain | author = Chadds Ford | publisher = Endo Pharmaceuticals | date = 2011-06-30 | url = http://phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-newsArticle&ID=1581163 | accessdate = 2012-05-11}}</ref><ref name="Gr端nenthal2010">{{cite patent | country = US | number = 20100331424 | status = Abandoned | title = Use of Axomadol for Treatment of Arthrosis Pain | pubdate = 2010-12-30 | fdate = 2010-09-10 | inventor = Schiene K, Bloms-Funke P, Bothmer J, Lefeber C | assign1 = Gr端nenthal GmbH | class = 514/650}}</ref> Development was halted after [[phases of clinical research|phase II]] [[clinical trial]]s as it did not meet the pre-determined [[clinical endpoint]]s.<ref name="Endo2011-2">{{cite press release | title = Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol | author = Chadds Ford | publisher = Endo Pharmaceuticals | date = 2011-08-17 | url = http://phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-newsArticle&ID=1597623 | accessdate = 2012-05-11}}</ref>

==See also==
* [[Tramadol]]

==References==
{{Reflist|2}}


{{Analgesics}}
{{Opioidergics}}

[[Category:Amines]]
[[Category:Analgesics]]
[[Category:Diols]]
[[Category:Opioids]]
[[Category:Abandoned drugs]]


{{analgesic-stub}}